

1. I hereby certify that this paper (along with any paper referred to as being attached enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: December 19, 2006

Signature:

Katherine L. Neville
(Katherine L. Neville)

Docket No.: 30694/39618A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Julian Andreev et al.

Application No.: 10/579,286

Confirmation No.: Not Yet Assigned

Filed: May 15, 2006

Art Unit: Not Yet Assigned

For: METHODS FOR IDENTIFYING
MODULATORS OF ACTIVE KIT
TYROSINE KINASE RECEPTOR

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR


1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30694/39618A. A copy of this paper is enclosed.

Dated: December 19, 2006

Respectfully submitted,

By 

Katherine L. Neville

Registration No.: 53,379

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/579,286
				Filing Date	May 15, 2006
				First Named Inventor	Julian Andreev
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	30694/39618A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-02/068308	06-06-2002	Fraser et al.	
	A2	US-4,518,584	05-21-1985	Mark et al.	
	A3	US-4,946,778	08-07-1990	Ladner et al.	
	A4	US-5,585,089	12-17-1996	Queen et al.	
	A5	US-5,643,759	07-01-1997	Pfreundschuh et al.	
	A6	US-5,693,762	12-02-1997	Queen et al.	
	A7	US-5,798,229	08-25-1998	Strittmatter et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-93/11236	06-10-1993	Medical Research Council		
	B2	WO-99/10494	03-04-1999	Genetech, Inc.		
	B3	WO-02/10339	02-07-2002	Ortho-McNeil Pharmaceutical, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Ashman, Int. J. Biochem. Cell. Biol., 31:1037-1051 (1999)	
	C2	Blume-Jensen et al., EMBO J., 12:4199-4209 (1993)	
	C3	Boer et al., Exp. Hematol., 31:512-520 (2003)	
	C4	Bolhuis et al., Cancer Immunol. Immunother., 34:1-8 (1991)	
	C5	Bowman et al., Oncogene, 19:2474-2488 (2000)	
	C6	Brockow et al., Curr. Opin. Allergy Clin. Immunol., 1:449-454 (2001)	
	C7	Cane et al., Science, 282:63-68 (1998)	
	C8	Carter et al., J. Hematol., 4:463-470 (1995)	
	C9	Dall'Acqua et al., Curr. Opin. Struct. Biol., 8:443-450 (1998)	
	C10	Darnell et al., Science, 264:1415-1421 (1994)	
	C11	Feger et al., Int. Arch. Allergy Immunol., 127:110-114 (2002)	
	C12	Fletcher et al., Hum. Pathol., 33:459-465 (2002)	
	C13	Frost et al., Mol. Cancer Ther., 1:1115-1124 (2002)	
	C14	Heinrich et al., Blood, 96:925-932 (2000)	
	C15	Heinrich et al., J. Clin. Oncol., 20:1692-1703 (2002)	
	C16	Holliger et al., Curr. Opin. Biotechnol., 4:446-449 (1993)	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/579,286
				Filing Date	May 15, 2006
				First Named Inventor	Julian Andreev
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	30694/39618A

C17	Hoogenboom et al., J. Mol. Biol., 227:381-388 (1992)	
C18	Jones et al., Nature, 321:522-525 (1986)	
C19	Jung et al., J. Immunol. Methods, 173:219-228 (1993)	
C20	Kortt et al., Biomol. Eng., 18:95-108 (2001)	
C21	Longley et al., Leuk. Res., 25:571-576 (2001)	
C22	Longley et al., Proc. Natl. Acad. Sci. USA, 96:1609-1614 (1999)	
C23	Ma et al., J. Invest. Dermatol., 114:392-394 (2000)	
C24	Marks et al., J. Mol. Biol., 222:581-597 (1991)	
C25	Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)	
C26	Myers, Curr. Opin. Biotechnol., 8:701-707 (1997)	
C27	Neuberger et al., Nature, 312:604-608 (1984)	
C28	Owens et al., J. Immunol. Methods, 168:149-165 (1994)	
C29	Pluckthun et al., Immunotechnology, 3:83-105 (1997)	
C30	Rader et al., Proc. Natl. Acad. Sci. USA, 95:8910-8915 (1998)	
C31	Renner et al., Immunol. Rev., 145:179-209 (1995)	
C32	Riechmann et al., Nature, 332:323-327 (1988)	
C33	Ryan et al., Oncologist, 7:531-538 (2002)	
C34	Segal et al., Immunobiology, 185:390-402 (1992)	
C35	Segal et al., J. Hematother., 4:377-382 (1995)	
C36	Strickland et al., Cancer Control, 8:252-261 (2001)	
C37	Takeda et al., Nature, 314:452-454 (1985)	
C38	Tatton et al., J. Biol. Chem., 278:4847-4853 (2003)	
C39	Todorovska et al., J. Immunol. Methods, 248:47-66 (2001)	
C40	Verhoeven et al., Science, 239:1534-1536 (1988)	
C41	Zermati et al., Oncogene, 22:660-664 (2003)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

939986